Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Aytu gains global license to pivotal study-ready protein kinase C β isoform (PKCβ) inhibitor, AR101 (enzastaurin) in rare disease indications. Program initially targeting vascular Ehlers-Danlos Syndrome (vEDS).
Lead Product(s): Enzastaurin
Therapeutic Area: Genetic Disease Product Name: AR101
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Aytu BioScience
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement April 12, 2021